ACR
Click for more information
8.33% 6.5¢ acrux limited

Ann: New Drug Application for AXIRON accepted for, page-15

  1. danny3
    1,539 Posts.
    lightbulb Created with Sketch. 5
    clock Created with Sketch.
    19/04/10
    19:01
    Post #: 6592057
    re: Ann: New Drug Application for AXIRON acce... The attraction of Acrux for me was originally the size and diversity of their product pipeline. So I'd really like to see some progress with that, not a narrow focus on Axiron.

    We're down to one big partner - Eli Lilly - and some minor ones - KV and lots of others with Evamist/Ellavie. And there haven't been any additions to the pipeline for some time.
    ACR Price at posting: $2.23 Sentiment: LT Buy Disclosure: Held
    Likes Created with Sketch.  Upvote
    lightbulb Created with Sketch.  Great analysis
    Stroke 3 Created with Sketch. Comments Created with Sketch. Reply

  2. Top Stories

 

Featured News

RNU Renascor wins a funding boost given it wants to produce a critical mineral – but $5M award pales in comparison to some
right-arrow Created with Sketch.
NEWS Hillcrest Energy Unveils Power Factor Correction Prototype to Meet Growing Demand
right-arrow Created with Sketch.
CXO Core Lithium narrowly beats guidance on FY24 spodumene production but 1Y returns still shattered
right-arrow Created with Sketch.
TX3 Canadian fieldwork yields multiple pegmatites for Trinex
right-arrow Created with Sketch.
NEWS Buying smarter as baby boomers get boost
right-arrow Created with Sketch.
ENR Encounter Resources flags latest niobium hits in fresh assay data
right-arrow Created with Sketch.
watchlist Created with Sketch. Add ACR (ASX) to my watchlist
(20min delay)
Last
6.5¢ 		Change
0.005(8.33%) 		Mkt cap ! $18.89M
Open High Low Value Volume
6.4¢ 6.5¢ 6.4¢ $3.399K 53.06K

Buyers (Bids)

No. Vol. Price($)
1 50000 6.2¢
 

Sellers (Offers)

Price($) Vol. No.
6.5¢ 70395 1
View Market Depth
Last trade - 15.57pm 11/07/2024 (20 minute delay) ?
ACR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.